0001209191-22-041339.txt : 20220706 0001209191-22-041339.hdr.sgml : 20220706 20220706182158 ACCESSION NUMBER: 0001209191-22-041339 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220705 FILED AS OF DATE: 20220706 DATE AS OF CHANGE: 20220706 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: McNeill Jonathan CENTRAL INDEX KEY: 0001824673 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39509 FILM NUMBER: 221070082 MAIL ADDRESS: STREET 1: C/O DYNE THERAPEUTICS, INC. STREET 2: 830 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Dyne Therapeutics, Inc. CENTRAL INDEX KEY: 0001818794 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 364883909 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1560 TRAPELO ROAD CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: (781) 786-8230 MAIL ADDRESS: STREET 1: 1560 TRAPELO ROAD CITY: WALTHAM STATE: MA ZIP: 02451 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-07-05 0 0001818794 Dyne Therapeutics, Inc. DYN 0001824673 McNeill Jonathan C/O DYNE THERAPEUTICS, INC. 1560 TRAPELO ROAD WALTHAM MA 02451 0 1 0 0 See Remarks Stock Option (right to buy) 5.54 2022-07-05 4 A 0 21666 0.00 A 2030-07-30 Common Stock 21666 21666 D The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an Investigational New Drug (IND) application submitted to the U.S. Food and Drug Administration (FDA) by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved. Senior Vice President of Business Development /s/ Richard Scalzo, Attorney-in-Fact 2022-07-06